Case number 3:17-cv-01076
Galderma Laboratories LP et al v. Actavis Laboratories UT Inc et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Nov 19, 2020 | 9 | Order Setting Deadline/Hearing (4) |
| Nov 19, 2020 | 10 | Summons Returned (2) |
| Nov 19, 2020 | 18 | Motion for Extension of Time to File Answer (2) |
| Nov 19, 2020 | 18 | Proposed Order (1) |
| Nov 19, 2020 | 21 | Motion to Dismiss (10) |
| Nov 19, 2020 | 25 | Motion to Dismiss (9) |
| Nov 19, 2020 | 25 | Proposed Order (1) |
| Nov 19, 2020 | 32 | Application for Admission Pro Hac Vice (3) |
| Nov 19, 2020 | 32 | Certificate of Good Standing (1) |
| Nov 19, 2020 | 32 | Proposed Order (1) |
| Nov 19, 2020 | 33 | Motion for Extension of Time to File Response/Reply (2) |
| Nov 19, 2020 | 33 | Proposed Order (1) |
| Nov 19, 2020 | 37 | Application for Admission Pro Hac Vice (3) |
| Nov 19, 2020 | 37 | Certificate of Good Standing (1) |
| Nov 19, 2020 | 37 | Proposed Order (1) |
| Nov 19, 2020 | 45 | Order Setting Deadline/Hearing (2) |
| Nov 19, 2020 | 47 | Motion for Leave to File (5) |
| Nov 19, 2020 | 47 | Exhibit(s) A - First Supplemental Complaint for Patent Infringement (6) |
| Nov 19, 2020 | 47 | Exhibit(s) F - U.S. Patent 9,782,425B2 (28) |
| Nov 19, 2020 | 47 | Proposed Order (1) |
| Nov 19, 2020 | 48 | Order Setting Deadline/Hearing (1) |
| Nov 19, 2020 | 60 | Memorandum Opinion and Order (30) |
| Nov 19, 2020 | 61 | Motion to Dismiss (3) |
| Dec 12, 2017 | N/A | Add and Terminate Judges (0) |
| Dec 11, 2017 | N/A | Case Transferred Out - District Transfer. (0) |
| Dec 11, 2017 | N/A | Acknowledgment of Case Transfer (0) |
| Dec 11, 2017 | 62 | Order on Motion to Dismiss (2) |
| Dec 11, 2017 | 63 | Order Transferring to Another District (1) |
| Dec 11, 2017 | 64 | Report to Patent/Trademark or Copyright Office (1) |
| Nov 17, 2017 | 59 | Amended Complaint (30) |
| Nov 17, 2017 | 59 | Complaint* (1) |
| Nov 6, 2017 | N/A | Order on Sealed and/or Ex Parte Motion (0) |
| Nov 2, 2017 | 52 | Notice (Other) (2) |
| Nov 2, 2017 | 53 | Appendix in Support (3) |
| Nov 2, 2017 | 53 | Declaration(s) of Jamil Alibhai (3) |
| Nov 2, 2017 | 53 | Exhibit(s) C1-Plaintiffs Second Amended Notice of Rule 30(b)(6) Deposition of De (7) |
| Nov 2, 2017 | 53 | Exhibit(s) C2-Excerpts from Teva Pharmaceutical Industries Limiteds 20-F (9) |
| Nov 2, 2017 | 53 | Exhibit(s) C3-Teva USA Specialty Medicines (3) |
| Nov 2, 2017 | 53 | Exhibit(s) C4-21 C.F.R. ยงยง 203.30-.35 (2017) (9) |
| Nov 2, 2017 | 53 | Exhibit(s) C5-Excerpts of Teva USA Code of Conduct (7) |
| Nov 2, 2017 | 53 | Exhibit(s) C6-Compiled Teva USA Phone Listings in NDTX (7) |
| Nov 2, 2017 | 53 | Exhibit(s) C7-Answer to Complaint (Keen v. Teva) (7) |
| Nov 2, 2017 | 53 | Exhibit(s) C8-Affidavit of Robert Bobrowski (Keen v. Teva) (2) |
| Nov 2, 2017 | 53 | Exhibit(s) C9-Excerpts of Oral Deposition of Robert Bobrowski (Keen v. Teva) (8) |
| Nov 2, 2017 | 53 | Exhibit(s) C10-Letter from Robert Bobrowski (Keen v. Teva) (1) |
| Nov 2, 2017 | 53 | Exhibit(s) C11-Answer to Plaintiffs Complaint (Stavropoulos v. Teva) (12) |
| Nov 2, 2017 | 53 | Exhibit(s) C12-Teva Pharmaceuticals USA, Inc. Annual Report filed with the Vermo (12) |
| Nov 2, 2017 | 53 | Exhibit(s) C13-Teva Sales and Marketing, Inc. Annual Report filed with the West (2) |
| Nov 2, 2017 | 55 | Appendix in Support (30) |
| Oct 31, 2017 | 50 | Response/Objection (4) |
| Oct 24, 2017 | 49 | Notice (Other) (3) |
| Oct 3, 2017 | N/A | Telephone Conference (0) |
| Sep 18, 2017 | 43 | Notice (Other) (7) |
| Sep 18, 2017 | 44 | Scheduling Conference (1) |
| Sep 12, 2017 | 42 | Notice (Other) (4) |
| Sep 12, 2017 | 42 | Exhibit(s) A - Bristol-Myers Squibb Co. v. Mylan Pharms Inc (21) |
| Sep 12, 2017 | 42 | Exhibit(s) B - Kranos IP Corp. v. Riddell Inc (14) |
| Sep 8, 2017 | N/A | Order on Application for Admission Pro Hac Vice (0) |
| Sep 7, 2017 | 40 | Notice (Other) (2) |
| Sep 1, 2017 | 38 | Reply (9) |
| Sep 1, 2017 | 39 | Reply (17) |
| Sep 1, 2017 | 39 | Exhibit(s) Appendix in Support (21) |
| Aug 25, 2017 | 36 | Status Report (15) |
| Aug 25, 2017 | 36 | Exhibit(s) A (3) |
| Aug 21, 2017 | N/A | Order on Motion to Extend Time to File Response/Reply (0) |
| Aug 18, 2017 | N/A | Order on Application for Admission Pro Hac Vice (0) |
| Aug 11, 2017 | 28 | Response/Objection (15) |
| Aug 11, 2017 | 29 | Appendix in Support (2) |
| Aug 11, 2017 | 29 | Exhibit(s) A - Declaration of Jamil N. Alibhai (3) |
| Aug 11, 2017 | 29 | Exhibit(s) 1 - Excerpts Teva's Form 20-F (5) |
| Aug 11, 2017 | 29 | Exhibit(s) 2 - Teva's 2nd Quarter 2017 Press Release (2) |
| Aug 11, 2017 | 30 | Response/Objection (30) |
| Aug 11, 2017 | 31 | Appendix in Support (3) |
| Aug 11, 2017 | 31 | Declaration(s) A - Declaration Steven B. Midgley (4) |
| Aug 11, 2017 | 31 | Exhibit(s) A-1 - Excerpts from Tevas Paragraph IV Notice (4) |
| Aug 11, 2017 | 31 | Declaration(s) B - Declaration Jamil N. Alibhai (6) |
| Aug 11, 2017 | 31 | Exhibit(s) B-1 - Excerpts from Tevas Form 20-F (10) |
| Aug 11, 2017 | 31 | Exhibit(s) B-2 - Teva Company Profile (3) |
| Aug 11, 2017 | 31 | Exhibit(s) B-3 - About Teva Generics (3) |
| Aug 11, 2017 | 31 | Exhibit(s) B-4 - Teva Investigational Sites (54) |
| Aug 11, 2017 | 31 | Exhibit(s) B-5 - Actavis Property Tax Appraisal (5) |
| Aug 11, 2017 | 31 | Exhibit(s) B-6 - Dallas Business Center (4) |
| Aug 11, 2017 | 31 | Exhibit(s) B-7 - Allergan Acquisition Press Release (5) |
| Aug 11, 2017 | 31 | Exhibit(s) B-8 - Teva USA License No. 38025 (2) |
| Aug 11, 2017 | 31 | Exhibit(s) B-9 - Teva USA License No. 93252 (2) |
| Aug 11, 2017 | 31 | Exhibit(s) B-10 - Actavis License No. 74065 (2) |
| Aug 11, 2017 | 31 | Exhibit(s) B-11 - Teva & Actavis Authorized Distributors (6) |
| Aug 11, 2017 | 31 | Exhibit(s) B-12 - Teva LinkedIn Profiles (34) |
| Aug 11, 2017 | 31 | Exhibit(s) B-13 - Actavis LinkedIn Profiles (10) |
| Aug 11, 2017 | 31 | Exhibit(s) B-14 - Exhibit 37 to Aralez's Response (3) |
| Aug 11, 2017 | 31 | Exhibit(s) B-15 - Teva Job Postings (6) |
| Aug 11, 2017 | 31 | Exhibit(s) B-16 - Forest Aquisition Press Release (6) |
| Aug 11, 2017 | 31 | Exhibit(s) B-17 - Teva's Acorda Amicus Brief (35) |
| Aug 11, 2017 | 31 | Exhibit(s) B-18 - Teva Reply (3) |
| Aug 11, 2017 | 31 | Exhibit(s) B-19 - Actavis v. USB Complaint (2) |
| Jul 27, 2017 | 26 | Order for Scheduling Order Proposal (7) |
| Jul 27, 2017 | 27 | Order Setting Deadline/Hearing (1) |
| Jul 24, 2017 | 24 | Cert. Of Interested Persons/Disclosure Statement (2) |
| Jul 21, 2017 | 22 | Appendix in Support (4) |
| Jul 21, 2017 | 23 | Appendix in Support (4) |
| Jul 19, 2017 | 20 | Summons Returned (2) |
| Jul 11, 2017 | N/A | Order on Motion for Extension of Time to File Answer (0) |
| Jul 10, 2017 | 13 | Notice of Attorney Appearance (2) |
| Jul 10, 2017 | 14 | Notice of Attorney Appearance (2) |
| Jul 10, 2017 | 15 | Amended Complaint (23) |
| Jul 10, 2017 | 15 | Exhibit(s) A (13) |
| Jul 10, 2017 | 15 | Exhibit(s) B (9) |
| Jul 10, 2017 | 15 | Exhibit(s) C (28) |
| Jul 10, 2017 | 15 | Exhibit(s) D (30) |
| Jul 10, 2017 | 15 | Exhibit(s) E (26) |
| Jul 10, 2017 | 16 | Request for Clerk to Issue Document (2) |
| Jul 10, 2017 | 17 | Summons Issued (2) |
| Jul 10, 2017 | 15 | Amended Complaint* (1) |
| Jul 6, 2017 | 12 | Amended Document (2) |
| Jun 29, 2017 | 11 | Order Setting Deadline/Hearing (4) |
| Jun 21, 2017 | 7 | Notice of Attorney Appearance (2) |
| Jun 21, 2017 | 8 | Notice of Attorney Appearance (2) |
| May 16, 2017 | 6 | Waiver of Service Executed (1) |
| Apr 24, 2017 | 1 | Main Document (18) |
| Apr 24, 2017 | 1 | Exhibit(s) A - US Patent No. 8,362,069 (13) |
| Apr 24, 2017 | 2 | Exhibit(s) B - US Patent No. 8,815,816 (9) |
| Apr 24, 2017 | 3 | Exhibit(s) C - US Patent No. 9,089,587 (28) |
| Apr 24, 2017 | 4 | Exhibit(s) D - US Patent No. 9,233,117 (30) |
| Apr 24, 2017 | 5 | Exhibit(s) E - US Patent No. 9,233,118 (26) |
| Apr 24, 2017 | 6 | Cover Sheet (1) |
| Apr 24, 2017 | 2 | Cert. Of Interested Persons/Disclosure Statement (2) |
| Apr 24, 2017 | 1 | Main Document (18) |
| Apr 24, 2017 | 1 | Exhibit(s) A - US Patent No. 8,362,069 (13) |
| Apr 24, 2017 | 2 | Exhibit(s) B - US Patent No. 8,815,816 (9) |
| Apr 24, 2017 | 3 | Exhibit(s) C - US Patent No. 9,089,587 (28) |
| Apr 24, 2017 | 4 | Exhibit(s) D - US Patent No. 9,233,117 (30) |
| Apr 24, 2017 | 5 | Exhibit(s) E - US Patent No. 9,233,118 (26) |
| Apr 24, 2017 | 6 | Cover Sheet (1) |
| Apr 24, 2017 | 2 | Cert. Of Interested Persons/Disclosure Statement (2) |
| Apr 24, 2017 | 1 | Main Document (18) |
| Apr 24, 2017 | 1 | Exhibit(s) A - US Patent No. 8,362,069 (13) |
| Apr 24, 2017 | 2 | Exhibit(s) B - US Patent No. 8,815,816 (9) |
| Apr 24, 2017 | 3 | Exhibit(s) C - US Patent No. 9,089,587 (28) |
| Apr 24, 2017 | 4 | Exhibit(s) D - US Patent No. 9,233,117 (30) |
| Apr 24, 2017 | 5 | Exhibit(s) E - US Patent No. 9,233,118 (26) |
| Apr 24, 2017 | 6 | Cover Sheet (1) |
| Apr 24, 2017 | 2 | Cert. Of Interested Persons/Disclosure Statement (2) |
| Apr 24, 2017 | N/A | Case Assigned/Reassigned (0) |
| Apr 21, 2017 | 1 | Complaint (18) |
| Apr 21, 2017 | 1 | Exhibit(s) B - US Patent No. 8,815,816 (9) |
| Apr 21, 2017 | 1 | Exhibit(s) C - US Patent No. 9,089,587 (28) |
| Apr 21, 2017 | 1 | Exhibit(s) D - US Patent No. 9,233,117 (30) |
| Apr 21, 2017 | 1 | Exhibit(s) E - US Patent No. 9,233,118 (26) |
| Apr 21, 2017 | 1 | Cover Sheet (1) |
| Apr 21, 2017 | 3 | Judge Lindsay (2) |
| Apr 21, 2017 | 4 | Summons Issued (6) |
| Apr 21, 2017 | 5 | Report to Patent/Trademark or Copyright Office (1) |
| Apr 21, 2017 | 1 | Complaint* (1) |
